

Visegrad research meeting 2026

Under the auspices
of Czech Myeloma Group

Wednesday

11. 3. 2026

Clarion Congress
Hotel Ostrava,
meeting room Rubín

Chairman: R. Hájek,

Visegrad Symposium is project of Czech Myeloma Group. It provides a platform for international communication in the management of patients with multiple myeloma. This year, in 2026, is symposium focused on the update of research and clinical activities of cell therapy and immunomonitoring.

WEDNESDAY 11. 3. 2026

16:45 – 17:00 Roman Hájek (Ostrava)
Welcome reception

PART I: MULTIPLE MYELOMA

17:00 – 17:10 Roman Hájek (Ostrava)
Isatuximab – RWE data in quadruplet era of MM treatment

17:10 – 17:25 Barbora Šušolová, Tereza Popková (Ostrava)
Safe administration of modern immunotherapy in an outpatient setting using telemedicine and home adverse event

17:25 – 17:40 Gábor Mikala (Budapest)
The effect of MYC rearrangements on myeloma survival

17:40 – 17:55 Varga Gergely (Budapest)
Ixazomib in the daratumumab era, real world analysis

17:55 – 18:10 Dominik Dytfeld (Poznań)
COBRA Results and TITAN Proposal of the Polish Myeloma Consortium

20 min COFFEE BREAK

PART II: CELL THERAPIES & IMMUNOMONITORING

18:30 – 18:45 Piotr Celichowski (Ostrava)
Current state of allogeneic CAR-T cell generation

18:45 – 19:00 Balázs Kardos (Budapest)
Genetic aberrations in Multiple Myeloma Revealed by Optical Genome Mapping

19:00 – 19:15 Ondřej Venglář (Ostrava)
Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8 color flow cytometry panel reveals differences among products kinetics and persistence

19:15 – 19:30 Juli R. Bagó (Ostrava)
Leveraging the cell competition phenomenon for cancer treatment

19:30 – 19:45 Zoltán Kellermayer (Pécs)
Bone marrow adipose tissue creates a plasma cell supporting niche within the bone marrow

PART III: DISCUSSION 20:00 +